David A. Reardon

62.5k total citations · 12 hit papers
560 papers, 34.0k citations indexed

About

David A. Reardon is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David A. Reardon has authored 560 papers receiving a total of 34.0k indexed citations (citations by other indexed papers that have themselves been cited), including 412 papers in Genetics, 195 papers in Oncology and 155 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David A. Reardon's work include Glioma Diagnosis and Treatment (406 papers), Brain Metastases and Treatment (111 papers) and Cancer Immunotherapy and Biomarkers (82 papers). David A. Reardon is often cited by papers focused on Glioma Diagnosis and Treatment (406 papers), Brain Metastases and Treatment (111 papers) and Cancer Immunotherapy and Biomarkers (82 papers). David A. Reardon collaborates with scholars based in United States, Germany and Switzerland. David A. Reardon's co-authors include Henry S. Friedman, Darell D. Bigner, James E. Herndon, Patrick Y. Wen, Allan H. Friedman, John H. Sampson, James J. Vredenburgh, Annick Desjardins, Roger E. McLendon and Jeremy N. Rich and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David A. Reardon

544 papers receiving 33.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IDH1andIDH2Mutations in Gliomas

2009 4.2k citations Roger E. McLendon, Henry S. Friedman et al. profile →
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

2010 2.7k citations Patrick Y. Wen, David A. Reardon et al. Journal of Clinical Oncology profile →
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology profile →
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

2020 946 citations David A. Reardon, Manmeet S. Ahluwalia et al. profile →
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

2007 815 citations James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research profile →
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
Phase II Trial of Gefitinib in Recurrent Glioblastoma

2003 558 citations Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology profile →
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

2015 471 citations Michael Weller, Mark R. Gilbert et al. profile →
Molecular targeted therapy of glioblastoma

2019 466 citations Émilie Le Rhun, Matthias Preusser et al. profile →
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

2015 410 citations Duane A. Mitchell, Gary E. Archer et al. profile →
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2017 362 citations Timothy F. Cloughesy, Shakti Ramkissoon et al. Neuro-Oncology profile →
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

2015 313 citations David A. Reardon, Morris D. Groves et al. Neuro-Oncology profile →

Peers

David A. Reardon

GENET

ONCOL

PRM

Timothy F. Cloughesy United States

Alba A. Brandes Italy

Warren Mason Canada

Henry S. Friedman United States

Patrick Y. Wen United States

Thierry Gorlia Belgium

J. Gregory Cairncross Canada

Roger E. McLendon United States

Roger Stupp Switzerland

Mark R. Gilbert United States

Timothy F. Cloughesy United States

David A. Reardon

20.4k ×1.0

GENET

10.9k ×1.0

6.3k ×0.7

ONCOL

6.5k ×0.9

PRM

7.8k ×1.1

Citations per year, relative to David A. Reardon David A. Reardon (= 1×) peers Timothy F. Cloughesy

Countries citing papers authored by David A. Reardon

Since Specialization

Citations

This map shows the geographic impact of David A. Reardon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Reardon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Reardon more than expected).

Fields of papers citing papers by David A. Reardon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Reardon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Reardon. The network helps show where David A. Reardon may publish in the future.

Co-authorship network of co-authors of David A. Reardon

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Reardon. A scholar is included among the top collaborators of David A. Reardon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Reardon. David A. Reardon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geurts, Marjolein, Franz Koenig, Burt Nabors, et al.. (2025). Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?. Neuro-Oncology Practice. 12(2). 291–300. 1 indexed citations

Rhun, Émilie Le, Sara Erridge, David A. Reardon, et al.. (2025). Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Network Open. 8(11). e2545578–e2545578.

Bernstock, Joshua D., Paramesh Karandikar, Jason Chen, et al.. (2024). Case Report: Low-grade glioma with NF1 loss of function mimicking diffuse intrinsic pontine glioma. Frontiers in Surgery. 11. 1356660–1356660. 1 indexed citations

Ahluwalia, Manmeet S., Michael J. Ciesielski, David A. Reardon, et al.. (2024). A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).. Journal of Clinical Oncology. 42(16_suppl). TPS2099–TPS2099. 4 indexed citations

Toker, Joseph, J. Bryan Iorgulescu, Alexander Ling, et al.. (2023). Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. 29(12). 2226–2238. 27 indexed citations

Lamba, Nayan, Malia McAvoy, Vasileios K. Kavouridis, et al.. (2022). Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. Neuro-Oncology Practice. 9(3). 201–207. 6 indexed citations

Bagley, Stephen, Shawn Kothari, Rifaquat Rahman, et al.. (2021). Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research. 28(4). 594–602. 104 indexed citations

Khasraw, Mustafa, Michael Weller, David Lorente, et al.. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab058–vdab058. 18 indexed citations

Vogelbaum, Michael A., Daria Krivosheya, Hamid Borghei‐Razavi, et al.. (2020). Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology. 22(11). 1568–1579. 42 indexed citations

10.

Iorgulescu, J. Bryan, Maya Harary, Cheryl K. Zogg, et al.. (2018). Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research. 6(9). 1039–1045. 56 indexed citations

11.

Nakashima, Hiroshi, Tran Nguyen, Kazue Kasai, et al.. (2018). Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clinical Cancer Research. 24(11). 2574–2584. 49 indexed citations

12.

Rhun, Émilie Le, Roger Stupp, Olivier Chinot, et al.. (2018). Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. European Journal of Cancer. 101. 95–104. 10 indexed citations

13.

Reardon, David A., Prafulla C. Gokhale, Sarah R. Klein, et al.. (2015). Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research. 4(2). 124–135. 302 indexed citations

14.

Reardon, David A., Morris D. Groves, Patrick Y. Wen, et al.. (2013). A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research. 19(4). 900–908. 91 indexed citations

15.

Chamberlain, Marc C., et al.. (2012). A novel treatment for glioblastoma: integrin inhibition. Expert Review of Neurotherapeutics. 12(4). 421–435. 29 indexed citations

16.

Reardon, David A., April Coan, James E. Herndon, et al.. (2011). Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. Journal of Clinical Oncology. 29(21). 2918–2923. 94 indexed citations

17.

Vredenburgh, James J., Annick Desjardins, David A. Reardon, et al.. (2011). The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. Clinical Cancer Research. 17(12). 4119–4124. 112 indexed citations

18.

Sampson, John H., Amy B. Heimberger, Gary E. Archer, et al.. (2010). Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(31). 4722–4729. 613 indexed citations breakdown →

19.

Sampson, John H., Gary E. Archer, Duane A. Mitchell, et al.. (2009). An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8(10). 2773–2779. 221 indexed citations

20.

Desjardins, Annick, David A. Reardon, James E. Herndon, et al.. (2008). Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clinical Cancer Research. 14(21). 7068–7073. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact